Abiraterone Acetate, Olaparib, and Prednisone in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer With DNA Repair Defects
Conditions: Prostate Cancer Metastatic Castration-Resistant; Abnormal DNA Repair; Hormone-Resistant Prostate Cancer; Metastatic Prostate Carcinoma; Stage IV Prostate Cancer Interventions: Drug: Olaparib; Drug: Abiraterone Acetate; Drug: Prednisone Sponsors: Northwestern University; AstraZeneca; National Cancer Institute (NCI) Not yet recruiting - verified January 2017
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Abiraterone Acetate | AstraZeneca | Cancer | Cancer & Oncology | Carcinoma | Gastroschisis Repair | Hormone Resistant Prostate Cancer | Hormones | Prednisone | Prostate Cancer